How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Iodine Contrast Agent API Market
- By Chemical Structure: Ionic Iodine Contrast Agents, Non-Ionic Iodine Contrast Agents, Iso-osmolar Iodine Contrast Agents
- By Application: Computed Tomography (CT) Imaging, Angiography, Urography, Myelography, Intravenous Pyelogram (IVP)
- By Formulation Type: Liquid Formulations, Powder Formulations, Ready-to-Use Solutions
- By End-User: Pharmaceutical Manufacturers, Diagnostic Imaging Centers, Hospitals and Clinics
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Ionic Iodine Contrast Agents leads By Chemical Structure at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 270 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.161 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.169 →
Full report · locked preview
Everything inside the Iodine Contrast Agent API Market report
A complete, evidence-based study - 11 chapters and 113 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Chemical Structure 3
Application 5
Formulation Type 3
End-User 3
Companies profiled
BASF SE
Jiangsu Hengrui Medicine Co. Ltd.
Jubilant Life Sciences Limited
Luye Pharma Group Ltd.
Sino Biopharmaceutical Limited
Mitsubishi Chemical Corporation
Bayer AG
Mallinckrodt Pharmaceuticals
Guerbet Group
Bracco Imaging S.p.A.
Fujifilm Holdings Corporation
IOL Chemicals and Pharmaceuticals
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →BASF SE
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Jiangsu Hengrui Medicine Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Jubilant Life Sciences Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Luye Pharma Group Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sino Biopharmaceutical Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Mitsubishi Chemical Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Mallinckrodt Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Guerbet Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Bracco Imaging S.p.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Fujifilm Holdings Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →IOL Chemicals and Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Spectrum Chemical Manufacturing Corp.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Lantheus Holdings Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Sagent Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,710M by 2033 · 9.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Ionic Iodine Contrast Agents51.3
- Non-Ionic Iodine Contrast Agents14.8
- Iso-osmolar Iodine Contrast Agents33.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$759.3M → $1,531M · 9.2%
Europe$529.2M → $1,109M · 9.7%
Asia Pacific$483.2M → $1,088M · 10.7%
Latin America$299.1M → $595.7M · 9.0%
Middle East and Africa$230.1M → $454.3M · 8.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.332026
9.332027
9.342028
9.362029
9.372030
9.372031
9.402032
9.412033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- BASF SE14.8
- Jiangsu Hengrui Medicine Co. Ltd.23.7
- Jubilant Life Sciences Limited12.4
- Luye Pharma Group Ltd.6.5
- Sino Biopharmaceutical Limited9.4
- Mitsubishi Chemical Corporation5.1
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Chemical Structure30.4%
Application18.4%
Formulation Type24.4%
End-User26.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.0
- Europe23.2
- Asia Pacific22.8
- Latin America12.5
- Middle East and Africa9.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| BASF SE | 86 | 80 | 79 | 73 | 77 | 97 | 82 |
| Jiangsu Hengrui Medicine Co. Ltd. | 76 | 74 | 70 | 71 | 76 | 77 | 74 |
| Jubilant Life Sciences Limited | 67 | 70 | 65 | 85 | 86 | 63 | 73 |
| Luye Pharma Group Ltd. | 59 | 79 | 79 | 68 | 68 | 78 | 72 |
| Sino Biopharmaceutical Limited | 52 | 57 | 52 | 51 | 67 | 71 | 58 |
| Mitsubishi Chemical Corporation | 48 | 48 | 46 | 60 | 60 | 53 | 53 |
| Bayer AG | 46 | 65 | 52 | 62 | 56 | 49 | 55 |
| Mallinckrodt Pharmaceuticals | 35 | 35 | 55 | 60 | 58 | 53 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- BASF SE
- Jiangsu Hengrui Medicine Co. Ltd.
- Jubilant Life Sciences Limited
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| BASF SE | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Jiangsu Hengrui Medicine Co. Ltd. | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Jubilant Life Sciences Limited | ◐ | ◐ | ◐ | ✓ | ✓ | − |
| Luye Pharma Group Ltd. | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Sino Biopharmaceutical Limited | − | ◐ | − | − | ◐ | ◐ |
| Mitsubishi Chemical Corporation | − | − | − | − | ◐ | − |
| Bayer AG | ◐ | ◐ | ◐ | ◐ | − | − |
| Mallinckrodt Pharmaceuticals | − | − | ◐ | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1BASF SE82
2Jiangsu Hengrui Medicine Co. Ltd.74
3Jubilant Life Sciences Limited73
4Luye Pharma Group Ltd.72
5Sino Biopharmaceutical Limited58
6Bayer AG55
7Mitsubishi Chemical Corporation53
8Mallinckrodt Pharmaceuticals49
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
BASF SE
Challenger3
Strong scale, closing on the leaders.
Jiangsu Hengrui Medicine Co. Ltd.Jubilant Life Sciences LimitedLuye Pharma Group Ltd.
Contender1
Focused players with pockets of strength.
Sino Biopharmaceutical Limited
Niche3
Specialists in a single segment or region.
Mitsubishi Chemical CorporationBayer AGMallinckrodt Pharmaceuticals
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Chemical Structure in North America, then scale across Iodine Contrast Agent API Market — a $165M beachhead inside a $2.38B market.
Beachhead (SOM)$165Mobtainable near-term
Serviceable (SAM)$918Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Ionic Iodine Contrast Agents
Best fit — highest urgency & budget in Chemical Structure.
Economic buyer77 fit
Non-Ionic Iodine Contrast Agents
Strong fit — clear ROI and a fast path to value.
End user68 fit
Iso-osmolar Iodine Contrast Agents
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Chemical Structure in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Formulation Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel26%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Chemical Structure leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Iodine Contrast Agent API Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified24%
Evaluation13%
Closed-won5%
$13.5KCAC
$47KLTV
3.5:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Iodine Contrast Agent API Market is a durable-growth opportunity — $10.1B by 2033, compounding at 8.7%.
TAM · 2025$5.16Btoday
TAM · 2033$10.1Bforecast
CAGR8.7%2027–2033
Cumulative$66.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$10.1BTotal addressable market
SAM$3.69BServiceable available market
SOM$685MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.7% CAGR
Demand compounds through 2033, outpacing GDP across Chemical Structure.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Chemical Structure moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$10.1BLarge & growingTAM by 2033 at 8.7% CAGR
$3.69BServiceable nowreachable with today’s model
$685MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.86BBear5.7% CAGR
$10.1BBase8.7% CAGR
$12.9BBull11.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Iodine Contrast Agent API Market — a $5.81B market by 2033. Plan: grow share from 9.9% to 18.4%.
Market size · 2033$5.81Btotal addressable
Market CAGR4.5%2027–2033
Target share18.4%from 9.9% today
Revenue ambition$1.07Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.9% | 18.4% | Ahead |
| Revenue | $611M | $1.07B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 30.3% | 44.8% | At risk |
| Customer retention | 84.6% | 96.8% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Chemical Structure
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Chemical Structure share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $138M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Chemical Structure leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Iodine Contrast Agent API Market conversation — a $7.11B market you can size, segment and defend in minutes.
Market size · 2033$7.11Btotal opportunity
Growth9.8%CAGR to 2033
Addressable buyers1,417+accounts in scope
Typical ROI7.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Chemical Structure
Goal Grow share in Chemical Structure
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.4×return on cost, year one
< 2 mopayback period
$73K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
BASF SEJiangsu Hengrui Medicine Co. Ltd.Jubilant Life Sciences LimitedLuye Pharma Group Ltd.Sino Biopharmaceutical LimitedMitsubishi Chemical CorporationBayer AGMallinckrodt Pharmaceuticals+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Iodine Contrast Agent API Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Iodine Contrast Agent API Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Iodine-containing Contrast Medium Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportIodine-131 Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportIodine-125 Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportIodinc-125 Seeds Source Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportIodinated Oil Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportIodinated Contrast Media in Interventional X-Ray Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportIodinated Contrast Media (ICM) Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportIodinated Contrast Market
Market size, share, segmentation and regional forecast.
$417M market · 2025 base year
View reportIn Vivo Visible Light Imaging System Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportIn Vivo Sustained Release Coatings Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportIn Vivo Preclinical Imaging System Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportIn Vivo Preclinical Imagers Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.